TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30167830

Group type: EXPERIMENTAL
Intervention: Indwelling catheter (French 16)
Number of subjects: 75

Group type: COMPARATOR
Intervention: No catheter
Number of subjects: 75
Study: 26260705

Group type: EXPERIMENTAL
Intervention: Intravenous ghrelin at 1 μg/kg or 2 μg/kg, twice daily for 3 weeks
Number of subjects: 18
Study: 26019878

Group type: EXPERIMENTAL
Intervention: 80% reduced basal insulin dose with reduced prandial bolus insulin and LGI carbohydrate feeding
Number of subjects: 10

Group type: COMPARATOR
Intervention: 100% basal insulin dose
Number of subjects: 10
Study: 23140985

Group type: EXPERIMENTAL
Intervention: Local anesthetics (A)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Local anesthetics and lavage (AL)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups (A and AL)
Number of subjects: 45
Study: 21228629

Group type: COMPARATOR
Intervention: RIX4414 vaccine stored at 2 °C‐8 °C (Group RIX4414_control, n = 171)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: RIX4414 vaccine stored at 37 °C for 7 days (Group RIX4414_37 °C, n = 47)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Placebo group (n = 25)
Number of subjects: 218
Study: 19480560

Group type: EXPERIMENTAL
Intervention: UK-453,061 (non-nucleoside reverse transcriptase inhibitor)
Number of subjects: 0
Study: 17541023

Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol (0.05 mg/d)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol (0.05 mg/d) + norethindrone acetate (NETA, 0.14 mg/d)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: GTN-D response
Number of subjects: 100
Study: 14720083

Group type: EXPERIMENTAL
Intervention: Data Safety Monitoring Boards (DSMBs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interim analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trial sponsor responsibility
Number of subjects: 0
Study: 11431238

Group type: EXPERIMENTAL
Intervention: Real rTMS (1 Hz, 110% motor threshold)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham rTMS (1 Hz, 20% motor threshold)
Number of subjects: 18
Study: 11930385

Group type: EXPERIMENTAL
Intervention: 6 grams of psyllium hydrophilic mucilloid per day
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 46
Study: 8852740

Group type: EXPERIMENTAL
Intervention: Maltose (0.05g maltose/kg body-weight/hour for 5 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucose (isocaloric completed nutritional solution)
Number of subjects: 0
Study: 1519576

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg evening dose
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg evening dose
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg evening dose
Number of subjects: 186
Study: 6826108

Group type: EXPERIMENTAL
Intervention: Bombesin (10 ng/kg/min)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Gastrin response to meal
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Bombesin
Number of subjects: 41
Study: 31475415

Group type: EXPERIMENTAL
Intervention: 1000 mg/day trans‐resveratrol
Number of subjects: 71

Group type: COMPARATOR
Intervention: placebo (methyl cellulose)
Number of subjects: 71
Study: 29318278

Group type: EXPERIMENTAL
Intervention: Idalopirdine 60 mg/d
Number of subjects: 2525

Group type: EXPERIMENTAL
Intervention: Idalopirdine 30 mg/d
Number of subjects: 2525

Group type: EXPERIMENTAL
Intervention: Idalopirdine 10 mg/d
Number of subjects: 2525

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2525
Study: 26924562

Group type: EXPERIMENTAL
Intervention: Cholesteatoma group
Number of subjects: 549

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 549
Study: 24794447

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 1μg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no intrathecal sufentanil)
Number of subjects: 40
Study: 22758921

Group type: EXPERIMENTAL
Intervention: Translating Research into Practice (TRIP) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 0
Study: 20921983

Group type: EXPERIMENTAL
Intervention: Probiotic mixture (Lactobacillus rhamnosus GR‐1 and Bifidobacterium adolescentis isolate in yogurt)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 36
Study: 18925530

Group type: COMPARATOR
Intervention: Urinary PC‐1 excretion in IgA nephropathy group
Number of subjects: 178

Group type: COMPARATOR
Intervention: Urinary NAGA excretion in membranous nephropathy group
Number of subjects: 178

Group type: COMPARATOR
Intervention: APN excretion in diabetic nephropathy group
Number of subjects: 178

Group type: COMPARATOR
Intervention: Urinary APN activity in type 1 and type 2 diabetic patients with microalbuminuria
Number of subjects: 178

Group type: COMPARATOR
Intervention: Urinary NAGA and DPP IV activities in type 2 diabetics with microalbuminuria
Number of subjects: 178

Group type: COMPARATOR
Intervention: Serum PC‐1 and APN activities in membranous nephropathy group
Number of subjects: 178

Group type: COMPARATOR
Intervention: Serum PC‐1 and DPP IV activities in IgA nephropathy patients
Number of subjects: 178

Group type: COMPARATOR
Intervention: Serum DPP IV and APN activity in type 2 diabetics with microalbuminuria
Number of subjects: 178
Study: 15741753

Group type: EXPERIMENTAL
Intervention: Satraplatin 100 mg/m² for 5 days plus prednisone 10 mg orally BID
Number of subjects: 50

Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 50
Study: 12393614

Group type: EXPERIMENTAL
Intervention: Mitoxantrone (10 mg/m² per day x 5) and Etoposide (100 mg/m² per day x 5)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Cytarabine (200 mg/m² per day x 7) and Daunorubicin (45 mg/m² per day x 3)
Number of subjects: 328
Study: 10355069

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Cordichin (fixed combination of chinidin and verapamil)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Chronic antiarrhythmic drug administration (Sotalol or Cordichin)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic medication (Sotalol or Cordichin)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 7860762

Group type: EXPERIMENTAL
Intervention: Chronic hyponatremia patients
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chronic hyponatremia patients (4 patients studied 8-14 weeks later)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 12
Study: 1789379

Group type: EXPERIMENTAL
Intervention: TRH (500 micrograms)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ethanol (0.8 g/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: TRH (500 micrograms) with ethanol
Number of subjects: 8
Study: 31422103

Group type: EXPERIMENTAL
Intervention: Electronic health record alerts and communication coaching for hospitalists
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no alerts or coaching)
Number of subjects: 14
Study: 30079432

Group type: EXPERIMENTAL
Intervention: Pioglitazone (up to 45 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 24
Study: 25622713

Group type: EXPERIMENTAL
Intervention: Autogenous intraoral block graft
Number of subjects: 10

Group type: COMPARATOR
Intervention: Autogenous particulate graft
Number of subjects: 10
Study: 24886444

Group type: EXPERIMENTAL
Intervention: ART sealant
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Fluoride-releasing resin sealant
Number of subjects: 280

Group type: COMPARATOR
Intervention: Topical fluoride application
Number of subjects: 280
Study: 22160347

Group type: EXPERIMENTAL
Intervention: Parent training intervention based on the TEACCH model
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waitlist group (control)
Number of subjects: 20
Study: 20299993

Group type: EXPERIMENTAL
Intervention: Peripheral nerve block (group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous opioids (group O)
Number of subjects: 60
Study: 17296819

Group type: EXPERIMENTAL
Intervention: Intravenous ferric gluconate (FG) 125 mg weekly for 8 weeks
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Oral ferrous sulfate 325 mg three times daily for 8 weeks
Number of subjects: 187

Group type: COMPARATOR
Intervention: No iron
Number of subjects: 187
Study: 16100476

Group type: EXPERIMENTAL
Intervention: Radionuclide angiography and SPECT using Tc‐99m MIBI
Number of subjects: 36
Study: 12269969

Group type: EXPERIMENTAL
Intervention: Alicaforsen (ISIS 2302) 300 mg, infused intravenously three times a week for 4 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Alicaforsen (ISIS 2302) 350 mg, infused intravenously three times a week for 4 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Alicaforsen (ISIS 2302) 250 mg, infused intravenously for patients weighing 36-50 kg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Alicaforsen (ISIS 2302) (all doses)
Number of subjects: 22
Study: 10194609

Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline formulation (200 mg anhydrous theophylline)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Market formulation (Theobid)
Number of subjects: 6
Study: 7763064

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 200 micrograms twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2305475

Group type: EXPERIMENTAL
Intervention: Outpatient surgery (group 2)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Inpatient surgery (group 1)
Number of subjects: 73
Study: 6104225

Group type: EXPERIMENTAL
Intervention: Axillary lymphoscintigraphy using intradermal injection of 100 muCi technetium‐99m antimony sulphide colloid in 0.1 ml buffer
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Axillary lymphoscintigraphy
Number of subjects: 30
Study: 31122527

Group type: EXPERIMENTAL
Intervention: Modified speculum application (109 patients, 124 cycles)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Conventional speculum application (110 patients, 132 cycles)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Modified speculum application
Number of subjects: 219

Group type: COMPARATOR
Intervention: Conventional speculum application
Number of subjects: 219
Study: 28258730

Group type: EXPERIMENTAL
Intervention: Alpha Lipoic Acid (ALA) oral supplementation
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 73
Study: 26021488

Group type: EXPERIMENTAL
Intervention: DHA+EPA (4 g/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 24333089

Group type: EXPERIMENTAL
Intervention: (C)ce(s) haplotype screening using allele-specific primer polymerase chain reactions
Number of subjects: 400
Study: 22152402

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19436683

Group type: EXPERIMENTAL
Intervention: Singing classes
Number of subjects: 43

Group type: COMPARATOR
Intervention: Handcraft work
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 43
Study: 15871484

Group type: EXPERIMENTAL
Intervention: 5-HT2A inhibitor (sarpogrelate 300 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: NSAIDs (diclofenac 75 mg/day)
Number of subjects: 40
Study: 12850609

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 10389358

Group type: EXPERIMENTAL
Intervention: Hebrew version of the Buschke Selective Reminding Memory Test
Number of subjects: 24
Study: 8905024

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: HRT + Tamoxifen
Number of subjects: 153

Group type: COMPARATOR
Intervention: HRT
Number of subjects: 153
Study: 2057005

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTA)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 23
Study: 6124268

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nadolol 80 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nadolol 160 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Atenolol and Nadolol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 15
Study: 30989682

Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with physicians and nursing professionals
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Physicians at different hierarchical levels
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Group membership processes
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Intergroup boundaries
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Experiences of clinicians
Number of subjects: 82
Study: 28371642

Group type: EXPERIMENTAL
Intervention: Emotional Faces Card Sorting Test (EFCST) with angry faces
Number of subjects: 80

Group type: COMPARATOR
Intervention: Wisconsin Card Sorting Test (WCST)
Number of subjects: 80
Study: 25240388

Group type: EXPERIMENTAL
Intervention: LLLT + calcium hydroxide
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Buckley's formocresol
Number of subjects: 20
Study: 23482513

Group type: EXPERIMENTAL
Intervention: White bread
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Whole wheat buttermilk bread
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Whole grain bread
Number of subjects: 11

Group type: COMPARATOR
Intervention: Pumpernickel rye bread (control)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: All breads
Number of subjects: 11
Study: 21147153

Group type: EXPERIMENTAL
Intervention: PriMa intervention (nine guided lessons with special posters and group discussions)
Number of subjects: 1553
Study: 18618462

Group type: EXPERIMENTAL
Intervention: de Quervain's screening tool (DQST)
Number of subjects: 93
Study: 16950469

Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (infused from 5 to 40 microg/kg/min)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group (115 patients without dobutamine-induced obstruction)
Number of subjects: 142
Study: 15052623

Group type: EXPERIMENTAL
Intervention: Increased resting mean arterial pressure (MAP) by 22% through sustained voluntary contraction of contralateral elbow flexors
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intermittent supramaximal electrical stimulation of the median nerve at 20 Hz for 2 min
Number of subjects: 8
Study: 11171670

Group type: EXPERIMENTAL
Intervention: Creatine supplementation during ischemic fatigue (IF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rest condition without creatine supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ischemic fatigue (IF) condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (1)H-MRS studies
Number of subjects: 0
Study: 9389922

Group type: EXPERIMENTAL
Intervention: Granisetron plus dexamethasone (20 mg i.v.)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Granisetron plus placebo (matching placebo)
Number of subjects: 110
Study: 7936823

Group type: EXPERIMENTAL
Intervention: Protein intakes ranging from 2.25 to 3.9 g.kg‐1.d‐1 and energy intakes ranging from 115 to 147 kcal.kg‐1.d‐1
Number of subjects: 44

Group type: COMPARATOR
Intervention: Two groups with differing energy intakes
Number of subjects: 44
Study: 2452392

Group type: EXPERIMENTAL
Intervention: COP-BLAM (5 cycles) and IMVP-16 (2 cycles) protocols
Number of subjects: 191

Group type: COMPARATOR
Intervention: Adjuvant radiotherapy
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Intensive polychemotherapy
Number of subjects: 191
Study: 31848066

Group type: EXPERIMENTAL
Intervention: Predictive model of in-hospital mortality based on prognostic variables (age, prosthetic valve IE, comorbidities, heart failure, renal failure, septic shock, Staphylococcus aureus, fungi, periannular complications, ventricular dysfunction, vegetations).
Number of subjects: 1135
Study: 28521546

Group type: EXPERIMENTAL
Intervention: Aloe vera gel
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sweet almond oil
Number of subjects: 160

Group type: COMPARATOR
Intervention: Base cream
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 160
Study: 27161619

Group type: EXPERIMENTAL
Intervention: Simple (provisional T-stenting) strategy
Number of subjects: 913
Study: 24360368

Group type: EXPERIMENTAL
Intervention: Daily oral cediranib 20mg
Number of subjects: 306

Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel chemotherapy
Number of subjects: 306
Study: 22841551

Group type: EXPERIMENTAL
Intervention: AgION catheter
Number of subjects: 86

Group type: COMPARATOR
Intervention: Non-impregnated catheter (Control)
Number of subjects: 86
Study: 20636655

Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR)
Number of subjects: 882

Group type: COMPARATOR
Intervention: Continuous CATI
Number of subjects: 882
Study: 17719167

Group type: EXPERIMENTAL
Intervention: L-arginine (3g daily)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 16634957

Group type: EXPERIMENTAL
Intervention: Deproteinized bovine mineral and a collagen membrane
Number of subjects: 120

Group type: COMPARATOR
Intervention: Papilla preservation flaps alone (Control)
Number of subjects: 120
Study: 14645968

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI) increase
Number of subjects: 0
Study: 11030401

Group type: EXPERIMENTAL
Intervention: Neoadjuvant hyperfractionated irradiation (20 Gy)
Number of subjects: 28
Study: 9167772

Group type: EXPERIMENTAL
Intervention: Single-drug parenteral polyestradiol phosphate (240 mg intramuscularly every second week for the first two months, then every fourth week)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Estrogen treatment vs. Orchidectomy
Number of subjects: 30
Study: 1493787

Group type: EXPERIMENTAL
Intervention: Conventional valproate (VPA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled release valproate (VPA-CR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: VPA and VPA-CR
Number of subjects: 0
Study: 3730866

Group type: EXPERIMENTAL
Intervention: Load perturbations (opposing the forthcoming movement)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unload perturbations (assisting the forthcoming movement)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perturbation size (large vs small)
Number of subjects: 0
Study: 29326145

Group type: EXPERIMENTAL
Intervention: Out-of-hospital cardiac arrest (OHCA) survivors (n=270)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Pre-event working OHCA survivors (n=135)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: OHCA survivors with cognitive impairment (n=55)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: OHCA survivors
Number of subjects: 287

Group type: COMPARATOR
Intervention: ST-segment-elevation myocardial infarction (STEMI) controls
Number of subjects: 287
Study: 26844840

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-alcohol
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Iodine-alcohol
Number of subjects: 1147
Study: 24289108

Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg once daily (QD)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Imatinib 400 mg QD
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg QD
Number of subjects: 108
Study: 22781199

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (BUD) + nebulized 0.5% salbutamol (150 µg/kg) + 0.025% ipratropium bromide (1 ml) + 0.05% budesonide (2 ml)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nebulized 0.5% salbutamol (150 µg/kg) + 0.025% ipratropium bromide (1 ml) + saline (2 ml)
Number of subjects: 40
Study: 19142560

Group type: EXPERIMENTAL
Intervention: Ultrasound evaluation of suprascapular notch
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Color Doppler ultrasound
Number of subjects: 50
Study: 17317135

Group type: EXPERIMENTAL
Intervention: Cold environment (‐18.0 degrees C, 39.2% relative humidity)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard environment (20.2 degrees C, 40.0% relative humidity)
Number of subjects: 20
Study: 14748763

Group type: COMPARATOR
Intervention: Dronedarone 800 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Dronedarone 1200 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Dronedarone 1600 mg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Dronedarone (800‐1600 mg daily) added to metoprolol (200 mg daily)
Number of subjects: 49
Study: 11606503

Group type: EXPERIMENTAL
Intervention: High-dose UDCA (20 mg/kg daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 9587719

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.3 mg (group 2)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.3 mg plus ketoprofen 100 mg and propacetamol 2 g (group 3)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Placebo (group 1)
Number of subjects: 291
Study: 7993155

Group type: EXPERIMENTAL
Intervention: High triglyceride level plus low HDL-C level
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low HDL-C level alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: High triglyceride level alone
Number of subjects: 0
Study: 2683824

Group type: EXPERIMENTAL
Intervention: Nimodipine (2 mg.h‐1)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 127
Study: 1150909

Group type: EXPERIMENTAL
Intervention: doxepin h.s.
Number of subjects: 40

Group type: COMPARATOR
Intervention: doxepin q.i.d.
Number of subjects: 40
Study: 30234805

Group type: EXPERIMENTAL
Intervention: Iliac crest bone graft harvested unilaterally through the primary midline incision.
Number of subjects: 90
Study: 28387664

Group type: EXPERIMENTAL
Intervention: Active hearing aids (HA) for 6 months
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo hearing aids for 6 months
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo group after secondary HA activation for 6 months
Number of subjects: 51